VYNE THERAPEUTICS INC (VYNE) Fundamental Analysis & Valuation

NASDAQ:VYNE • US92941V3087

0.5951 USD
+0.01 (+2.16%)
At close: Mar 6, 2026
0.5799 USD
-0.02 (-2.55%)
After Hours: 3/6/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This VYNE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall VYNE gets a fundamental rating of 3 out of 10. We evaluated VYNE against 193 industry peers in the Pharmaceuticals industry. VYNE has a great financial health rating, but its profitability evaluates not so good. VYNE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. VYNE Profitability Analysis

1.1 Basic Checks

  • In the past year VYNE has reported negative net income.
  • In the past year VYNE has reported a negative cash flow from operations.
  • In the past 5 years VYNE always reported negative net income.
  • VYNE had a negative operating cash flow in each of the past 5 years.
VYNE Yearly Net Income VS EBIT VS OCF VS FCFVYNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

  • The Return On Assets of VYNE (-87.81%) is worse than 75.65% of its industry peers.
  • With a Return On Equity value of -95.38%, VYNE is not doing good in the industry: 62.18% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -87.81%
ROE -95.38%
ROIC N/A
ROA(3y)-58.82%
ROA(5y)-68.56%
ROE(3y)-67.97%
ROE(5y)-85.75%
ROIC(3y)N/A
ROIC(5y)N/A
VYNE Yearly ROA, ROE, ROICVYNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

1.3 Margins

  • VYNE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VYNE Yearly Profit, Operating, Gross MarginsVYNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. VYNE Health Analysis

2.1 Basic Checks

  • VYNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VYNE has been increased compared to 1 year ago.
  • The number of shares outstanding for VYNE has been increased compared to 5 years ago.
  • There is no outstanding debt for VYNE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VYNE Yearly Shares OutstandingVYNE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
VYNE Yearly Total Debt VS Total AssetsVYNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • VYNE has an Altman-Z score of -32.44. This is a bad value and indicates that VYNE is not financially healthy and even has some risk of bankruptcy.
  • VYNE's Altman-Z score of -32.44 is on the low side compared to the rest of the industry. VYNE is outperformed by 87.05% of its industry peers.
  • VYNE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -32.44
ROIC/WACCN/A
WACC9.34%
VYNE Yearly LT Debt VS Equity VS FCFVYNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

2.3 Liquidity

  • VYNE has a Current Ratio of 12.53. This indicates that VYNE is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 12.53, VYNE belongs to the best of the industry, outperforming 81.35% of the companies in the same industry.
  • A Quick Ratio of 12.53 indicates that VYNE has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 12.53, VYNE belongs to the top of the industry, outperforming 81.35% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.53
Quick Ratio 12.53
VYNE Yearly Current Assets VS Current LiabilitesVYNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. VYNE Growth Analysis

3.1 Past

  • VYNE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 86.65%, which is quite impressive.
  • VYNE shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.77%.
  • Measured over the past years, VYNE shows a very negative growth in Revenue. The Revenue has been decreasing by -18.63% on average per year.
EPS 1Y (TTM)86.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.64%
Revenue 1Y (TTM)13.77%
Revenue growth 3Y-18.63%
Revenue growth 5YN/A
Sales Q2Q%54.76%

3.2 Future

  • The Earnings Per Share is expected to decrease by -23.52% on average over the next years. This is quite bad
  • The Revenue is expected to grow by 147.97% on average over the next years. This is a very strong growth
EPS Next Y14.28%
EPS Next 2Y0.36%
EPS Next 3Y-21.43%
EPS Next 5Y-23.52%
Revenue Next Year-43.75%
Revenue Next 2Y-18.99%
Revenue Next 3Y-25.99%
Revenue Next 5Y147.97%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VYNE Yearly Revenue VS EstimatesVYNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2029 2030 2031 2032 2033 50M 100M 150M 200M
VYNE Yearly EPS VS EstimatesVYNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

0

4. VYNE Valuation Analysis

4.1 Price/Earnings Ratio

  • VYNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VYNE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VYNE Price Earnings VS Forward Price EarningsVYNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VYNE Per share dataVYNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • A cheap valuation may be justified as VYNE's earnings are expected to decrease with -21.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.36%
EPS Next 3Y-21.43%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VYNE Dividend Analysis

5.1 Amount

  • No dividends for VYNE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VYNE Fundamentals: All Metrics, Ratios and Statistics

VYNE THERAPEUTICS INC

NASDAQ:VYNE (3/6/2026, 8:00:02 PM)

After market: 0.5799 -0.02 (-2.55%)

0.5951

+0.01 (+2.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-27
Earnings (Next)05-06
Inst Owners26.82%
Inst Owner Change106.98%
Ins Owners1.21%
Ins Owner Change-1.66%
Market Cap19.83M
Revenue(TTM)570.00K
Net Income(TTM)-26.48M
Analysts78
Price Target3.32 (457.89%)
Short Float %1.73%
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)14.71%
Min Revenue beat(2)-36.27%
Max Revenue beat(2)65.69%
Revenue beat(4)2
Avg Revenue beat(4)67.65%
Min Revenue beat(4)-54.9%
Max Revenue beat(4)296.08%
Revenue beat(8)4
Avg Revenue beat(8)38.73%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)50%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 34.79
P/FCF N/A
P/OCF N/A
P/B 0.71
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.93
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.99
OCFYN/A
SpS0.02
BVpS0.83
TBVpS0.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -87.81%
ROE -95.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.82%
ROA(5y)-68.56%
ROE(3y)-67.97%
ROE(5y)-85.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.53
Quick Ratio 12.53
Altman-Z -32.44
F-Score5
WACC9.34%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.64%
EPS Next Y14.28%
EPS Next 2Y0.36%
EPS Next 3Y-21.43%
EPS Next 5Y-23.52%
Revenue 1Y (TTM)13.77%
Revenue growth 3Y-18.63%
Revenue growth 5YN/A
Sales Q2Q%54.76%
Revenue Next Year-43.75%
Revenue Next 2Y-18.99%
Revenue Next 3Y-25.99%
Revenue Next 5Y147.97%
EBIT growth 1Y31.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-41.82%
EBIT Next 3Y-19.69%
EBIT Next 5YN/A
FCF growth 1Y2.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.5%
OCF growth 3YN/A
OCF growth 5YN/A

VYNE THERAPEUTICS INC / VYNE FAQ

What is the fundamental rating for VYNE stock?

ChartMill assigns a fundamental rating of 3 / 10 to VYNE.


Can you provide the valuation status for VYNE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to VYNE THERAPEUTICS INC (VYNE). This can be considered as Overvalued.


Can you provide the profitability details for VYNE THERAPEUTICS INC?

VYNE THERAPEUTICS INC (VYNE) has a profitability rating of 0 / 10.


What is the earnings growth outlook for VYNE THERAPEUTICS INC?

The Earnings per Share (EPS) of VYNE THERAPEUTICS INC (VYNE) is expected to grow by 14.28% in the next year.